Erivedge vismodegib regulatory update

Curis said partner Roche submitted a regulatory application to Australia's Therapeutic Goods Administration ( TGA) for Erivedge vismodegib to treat advanced basal cell carcinoma (BCC) in adults who are not candidates for surgery. The submission triggers a $4 million milestone payment from Roche to Curis, which is eligible for an additional milestone payment upon Australian approval of the product and royalties. ...